
    
      The study consists of the following parts:

        -  a Screening Visit

        -  an MRI scanning visit

        -  an in-clinic stay which includes: a Safety Baseline one day prior to dosing, a one-day
           [11C]-Lu AF88434 imaging session consisting of a baseline PET measurement and a
           post-dose PET measurement conducted after the administration of a single oral dose of Lu
           AF88434, pharmacokinetic (PK) sampling and safety assessments throughout the period

        -  a Follow-up Visit 7 days after dosing
    
  